Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.

M L Randi1, M Mares, F Fabris

  • 1Institute of Medical Semeiotics, University of Padua Medical School, Italy.

Arzneimittel-Forschung
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia.

Journal of clinical immunology·1996
Same author

Unexpected low prevalence of FVIII gene inversion in severe hemophilia A patients from north-eastern Italy.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1996
Same author

Pitfalls of protein C assays in patients with activated protein C resistance.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1996
Same author

Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma.

Blood·1996
Same author

Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation.

Thrombosis and haemostasis·1996
Same author

Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1996
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Ticlopidine improves walking distance in peripheral atherosclerotic disease (PAD) patients by reducing activated fibrinogen, not by altering its production or destruction. This study investigated the drug

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Peripheral atherosclerotic disease (PAD) is characterized by claudication, impacting patient mobility.
  • Ticlopidine is known to reduce plasma fibrinogen levels.
  • The mechanism behind ticlopidine's effect on fibrinogen requires clarification.

Purpose of the Study:

  • To evaluate the effect of ticlopidine on maximum walking distance in PAD patients.
  • To investigate whether ticlopidine decreases plasma fibrinogen through increased destruction or decreased production.
  • To explore the mechanism of ticlopidine-induced fibrinogen reduction.

Main Methods:

  • 15 PAD patients received ticlopidine for 3 months.
  • Evaluated maximum walking distance and plasma fibrinogen levels.

Related Experiment Videos

  • Assessed coagulable protein, fibrinogen antigen, 125I-fibrinogen survival, euglobulin lysis time, and plasminogen.

    • Main Results:

    • Ticlopidine treatment improved maximum walking distance in PAD patients.
    • Plasma fibrinogen levels, along with other coagulation and fibrinolysis markers, remained unchanged in the ticlopidine group and the control group (acetylsalicylic acid + dipyridamol).
    • The study ruled out increased fibrinogen destruction or decreased production as mechanisms for ticlopidine's effect.

    Conclusions:

    • Ticlopidine enhances walking ability in PAD patients.
    • The observed decrease in plasma fibrinogen is not due to altered production or degradation.
    • Ticlopidine likely reduces activated fibrinogen by inhibiting its binding to platelets.